<DOC>
	<DOCNO>NCT02927249</DOCNO>
	<brief_summary>This randomized phase III trial study well aspirin work prevent cancer come back ( recurrence ) patient human epidermal growth factor receptor 2 ( HER2 ) breast cancer chemotherapy , surgery , and/or radiation therapy . Aspirin drug reduces pain , fever , inflammation , blood clotting . It also study cancer prevention . Giving aspirin may reduce rate cancer recurrence patient breast cancer .</brief_summary>
	<brief_title>Aspirin Preventing Recurrence Cancer Patients With Node Positive HER2 Negative Stage II-III Breast Cancer After Chemotherapy , Surgery , and/or Radiation Therapy</brief_title>
	<detailed_description>This randomized double-blind placebo-controlled phase III trial aspirin ( 300 mg daily ) early stage node-positive HER2 negative breast cancer patient . Patients randomize 1:1 within stratum define : Hormone Receptor status ( HR positive v HR negative ) , body mass index ( &lt; 30 v ≥ 30 kg/m2 ) stage ( Stage II v III ) . The primary objective trial compare effect aspirin versus placebo upon invasive disease free survival ( iDFS ) . Primary objective To compare effect aspirin ( 300 mg daily ) versus placebo upon invasive disease free survival ( iDFS ) early stage node-positive HER2 negative breast cancer patient . Secondary objective 1 . To compare effect aspirin versus placebo early stage node-positive HER2 negative breast cancer patient upon : 1 . Distant disease-free survival 2 . Overall survival 3 . Cardiovascular disease ( see Section11.3 ) 2 . To compare toxicity aspirin versus placebo early stage node-positive HER2 negative breast cancer patient . 3 . To assess adherence aspirin placebo among early stage node-positive HER2 negative breast cancer patient . 4 . To bank tumor germline deoxyribonucleic acid ( DNA ) , plasma urine collect baseline sequential plasma urine collect 2 year later future measurement inflammatory marker . 5 . To determine subgroups participant characterize lifestyle factor associate great inflammation great benefit aspirin versus placebo upon iDFS . Patients follow 10 year study enrollment .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<criteria>1 . Documentation Disease Histologic Documentation : Histologic documentation woman men node positive , HER2 negative , anatomic stage II III breast carcinoma within one year diagnosis free recurrence . If neoadjuvant therapy receive , either initial clinical stage ( determined physical radiologic examination ) postoperative pathologic stage use eligibility purpose , high stage determine eligibility . Histologic documentation node positivity require . 2 . Disease status Any ER/PgR status allow . 3 . Prior Treatment Prior adjuvant treatment chemotherapy and/or endocrine therapy , determine treat physician , allow . The last dose chemotherapy radiation therapy must least 60 day prior study registration . Concurrent hormonal therapy allow . 4 . Regular NSAID/aspirin use ( define ≥ 5 day per week ) allow aspirin and/or NSAIDs stop one year prior study entry throughout study period . Participants encourage use acetaminophen minor pain fever . 5 . Patients must enrol within 1 year diagnosis . 6 . Age &gt; 18 &lt; 70 year age . 7 . ECOG performance status 02 . 8 . Patients prior history gastric/duodenal ulcer document endoscopy enrol long ulcer cause bleed require blood transfusion/major intervention . 9 . For patient Helicobacter pylori positive , course Helicobacter pylori eradication treatment must complete . 10 . No history GI bleed require blood transfusion , endoscopic operative intervention . 11 . No history prior stroke ( hemorrhagic ischemic ) . 12 . No concurrent anticoagulation warfarin heparin clopidogrel oral direct thrombin inhibitor . 13 . No history atrial fibrillation myocardial infarction . 14 . No history grade 4 hypertension , define hypertension result lifethreatening consequence ( e.g. , malignant hypertension , transient permanent neurologic deficit , hypertensive crisis ) . 15 . No chronic ( duration &gt; 30 day ) daily use oral steroid . 16 . No known allergy aspirin . 17 . No prior malignancy type within past 5 year breast cancer , basal squamous cell carcinoma skin carcinoma situ cervix . 18 . Concurrent enrollment nonchemotherapy treatment trial allow , long trial allows concurrent daily aspirin use . 19 . Required Initial Laboratory Values Platelet count ≥ 100,000/mm3</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>